Summary Forty-three children with malignant soft tissue sarcomas (IRS Groups II-IV) were treated with a rapid dose delivery chemotherapy protocol comprising six courses of vincristine, adriamycin and cyclophosphamide, given in most cases within 8 weeks (Rapid VAC). This was followed in 36 patients by high dose melphalan with autologous bone marrow rescue. Twenty-six patients also received irradiation to the site of primary tumour.
For over a decade the management of childhood rhabdomyosarcomas has been based on prolonged chemotherapy with cyclophosphamide based regimens (King et al., 1981; Hays, 1982; Kingston et al., 1983) . The duration of treatment has been reduced to 1-2 years in most large studies but for patients with non localised disease this is rarely less than 9 to 12 months. The feasibility of delivering a single high dose of an alkylating agent, melphalan, using autologous bone marrow rescue led to the introduction of this treatment for these patients at the Royal Marsden. From 1981-89, this was the standard treatment for such patients. The backbone of the treatment is weekly administration of moderate dose VAC which, in most patients, is followed by high dose melphalan. The decision to use radiotherapy or surgery is individualised as is inevitable with a tumour which affects many different primary sites. In this decision the patient's age, tumour histology and initial extent of disease is taken into consideration.
The aim of this treatment strategy was to intensify and shorten chemotherapy in the hope that rapid drug delivery and high dose intensity would improve the response at the primary site and control of micrometastatic disease. It was hoped that in some patients, particularly the younger ones, radiation treatment with its attendant sequelae on growth might be avoided.
Patients and methods
Forty-three patients without complete resection of primary tumour have been treated with the Rapid VAC regimen. Their initial stage and site are summarised on The treatment strategy is summarised in Figure 1 . Drug doses in Rapid VAC are cyclophosphamide 400 mg m-2, vincristine 1.5 mg m-2, adriamycin 40 mg m-2. Courses were given at weekly intervals providing the neutrophil count was > 1.0 x 109 -1 and platelet count > 100 x I09 1-'. Treatment was given within 8 weeks in 46% of patients and within 10 weeks in a further 30%. In 10% treatment was delayed for > 10 weeks because of recurring prolonged marrow suppression. In the remaining patients treatment was changed due to poor response before completion of the Rapid VAC regimen and in one patient treatment was terminated prematurely due to unacceptable marrow suppression and mucositis.
High dose melphalan was given 6-8 weeks after completion of Rapid VAC. The dose ranged from 140-220 mg m-2 and unpurged, non cryopreserved marrow was reinfused at 12-24 h after melphalan (Figure 2 ). Cyclophosphamide 'priming' was used routinely with 300mg m2i.v. given 1 week prior to melphalan. This has been shown to significantly reduce intestinal toxicity and may shorten the period of neutropaenia (Selby et al., 1987; Hedley et al., 1978) .
Eight patients with either metastatic disease or refractory primary tumour after Rapid VAC received second line chemotherapy with etoposide ± cisplatin and five of these were given high dose carboplatin in combination with melphalan as megatherapy (Pinkerton et al., 1989 Table II with details of the relapse sites. In IRS Group II two out of four have relapsed, in Group III, 10/27 have relapsed or progressed and four of these are in second complete remission. In Group IV, patients eight out of 12 have relapsed.
The actuarial survival of the two largest subgroup of patients is shown in Figure 3 . The progression free survival is shown in Figure 4 .
Details of relapse sites are given in Table II . For the largest subgroup -IRS Group III -40% of patients that relapsed are in second CR, resulting in a survival rate at 3 years of 67%. Only 20% of those with metastatic disease at presentation survive. in terms of initial response rate (Bramwell et al., 1986;  80-.in . The SIOP approach has been followed by the German CWS studies where vincristine, actinomycin, 70- adriamycin and ifosfamide are given as initial induction 60-.~n_ chemotherapy and both surgery and radiotherapy are reduced to a minimum (Belasco et al., 1987 (Bagnulo et al., 1985) . The strategy of rapid dose delivery with high dose intensity requires evaluation (DeVita, 1986) . Dose intensity has been demonstrated to correlate with initial response rates in some adult tumours (Hryniuk et al., 1986) . Rapid drug delivery, minimising the interval between tumour exposure to active agents has been used in malignant germ cell tumours, non Hodgkin's lymphoma, and also, recently, in neuroblastoma with encouraging results (Pearson et al., 1988; Hann et al., 1988; Horwich et al., 1989) . With the doses used in the Rapid VAC regimen several courses of chemotherapy can be given within a short period. Although the initial complete response rate with Rapid VAC is lower than that reported in the SIOP and CWS studies, the initial evaluation is after only 10-12 weeks rather than 3-4 months. The percentage of initially refractory patients with the Rapid VAC regimen is comparable to that in other studies i.e. 10-20%. In one study where response in Groups III/IV patients was assessed after -8 weeks CVAct, CR + PR rate = 54% (Carli et al., 1988) . For these two groups the response rate with Rapid VAC was 78% suggesting there may be some advantage to this schedule.
The early introduction of melphalan allows the administration of a high total dose of effective alkylating agent in a minimum period of time. The overall duration of therapy is reduced to approximately 3 months which has clear advantages in terms of patient acceptability. The toxicity of the high dose melphalan is not worse than that associated with either the high dose IVAD regimens containing 9 g of ifosfamide or the IRS 3 VAC + platinum and etoposide. There was a single toxic death associated with the melphalan regimen but it was generally well tolerated and the duration of hospital stay was not particularly long.
Within the limitations of patient numbers, the overall outcome with this approach is encouraging. Fifty-five per cent actuarial progression free survival at 3 years for IRS Group III patients is comparable to that reported by other groups with up to 2 years of VAC chemotherapy (IRS 1 42%) (Maurer et al., 1988) . When analysed on the basis of SIOP staging which emphasises regional extension of primary tumour progression free survival for Stage II patients is again 55% (survival 62%). This is similar to the result with SIOP regimens using IVA, as in the SIOP regimen MMT '84 (50% at 3 years). The salvage rate in MMT '84 appears higher with 67% surviving at 3 years and may be due to the absence of initial irradiation in all these cases.
The combination of etoposide and cisplatin is active in relapsed sarcomas (Carli et al., 1987; Castello et al., 1988) and it might be possible to incorporate these drugs in a rapid dose delivery schedule combined with the Rapid VAC regimen. The failure of the IRS to demonstrate benefit from the addition of these drugs may reflect the small dose of etoposide used and the overall drug scheduling.
The effectiveness in another high risk group -the parameningeal tumours -is unclear due to the small number but with HDM after conventional VAC only 30% DFS has been reported (Kingston et at., 1985) , despite aggressive radiotherapy. It is possible that delay in the timing of the latter may be of significance and outcome appears to be better in both STOP and IRS studies with early radiotherapy (before 8 weeks). This is the one tumour site where the strategy of delaying irradiation until after prolonged chemotherapy is inappropriate.
Results in patients with metastatic disease are disappointing and no significant benefit was apparent using this approach, with a survival of only 25%. The current SIOP MMT '89 regimen includes an intensive multiagent regimen for metastatic disease with pulses of carboplatin/epirubicin; ifosfamide/actinomycin; ifosfamide-etoposide. In that study, dose escalation with high dose carboplatin, busulphan and thiotepa, is being evaluated in refractory patients with a view to future incorporation in a first remission regimen.
There is understandable concern about the late effects of high dose alkylating agent administration. It is not clear, however, that a single dose of 200 mg m-2 of melphalan is worse than 54 g of ifosfamide, which is delivered in six courses of the current SIOP regimen, or the 10 g of cyclophosphamide delivered in 12 months of the IRS 3 protocol (Watson et al., 1985; Byrne et al., 1987) . The exact risk of infertility or second malignancies after a single high dose of melphalan in children is not clear and requires further study (Hartmann et al., 1984) . Adverse effects on endocrine function have been suggested but these are yet to be confirmed in larger series (Kellie et al., 1987) .
The occurrence of one major cardiotoxicity in 43 patients and possible cardiac contribution to toxic death in one other is of concern but the former case was a protocol violation who received eight courses in 10 weeks. A detailed cardiological follow-up is currently underway to try and clarify this issue and to date has not revealed a high incidence of cardiac toxicity.
It would seem prudent, however, to consider replacement of adriamycin with actinomycin or alternate these two agents in any future regimen.
This study was started at a time when 2 years of VAC plus irradiation was used for IRS Group II cases. It is possible that Rapid VAC alone without melphalan is sufficient chemotherapy for some of these patients. With the IVA regimen (SIOP MMT '84) irradiation was omitted in the majority of patients but the local relapse rate was higher than in IRS studies. Whether the use of melphalan could reduce this local relapse rate is unproven, and the late effects of this treatment modality may be different but no less significant than irradiation. The SIOP group has chosen to increase the dose of ifosfamide in these patients which may also have its own late sequelae.
Only six of the ten non metastatic patients who were not irradiated received melphalan, so no conclusion can be drawn regarding the effect of this procedure on local control.
For some patients with regional disease (mainly IRS Group III or SIOP Stage II) it is likely that the intensification of chemotherapy in this study allowed omission or reduction of wide field irradiation -of particular importance for the younger child and those with genitourinary and head and neck primaries.
In conclusion, the Rapid VAC/melphalan regimen is a well tolerated treatment programme generally requiring only 3-4 weeks of hospital admission. Encouraging results were seen in standard risk patients but alternative strategies are still required for high risk patients such as those with node positive, parameningeal or metastatic disease. This approach has the advantages of brevity and, possibly, increased efficacy due to rapid dose delivery and high dose intensity. The increasing availability of haematological growth factors (Metcalf et al., 1989) or perhaps the use of additional peripheral stem cell harvest (Watanabe et at., 1989) could further reduce the duration of hospitalisation and treatment morbidity. Moreover, the former could facilitate the administration of VAC in the prescribed time.
